| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 230 | 2026 | 599 | 10.940 |
Why?
|
| Fetus | 92 | 2021 | 125 | 8.840 |
Why?
|
| Female | 249 | 2026 | 4060 | 7.290 |
Why?
|
| Animals | 205 | 2026 | 1875 | 7.070 |
Why?
|
| Obesity | 28 | 2025 | 226 | 6.990 |
Why?
|
| Prenatal Exposure Delayed Effects | 39 | 2026 | 93 | 6.960 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 17 | 2026 | 25 | 5.280 |
Why?
|
| Amniotic Fluid | 39 | 2011 | 44 | 4.790 |
Why?
|
| Acidosis | 17 | 2023 | 30 | 4.650 |
Why?
|
| Fetal Growth Retardation | 25 | 2019 | 42 | 4.510 |
Why?
|
| Deglutition | 38 | 2005 | 40 | 4.200 |
Why?
|
| Rats | 71 | 2026 | 571 | 3.900 |
Why?
|
| Sheep | 95 | 2015 | 132 | 3.790 |
Why?
|
| Malnutrition | 13 | 2026 | 51 | 3.720 |
Why?
|
| Fetal Development | 16 | 2019 | 28 | 3.680 |
Why?
|
| Humans | 112 | 2025 | 6794 | 3.320 |
Why?
|
| Animals, Newborn | 36 | 2026 | 112 | 3.250 |
Why?
|
| Rats, Sprague-Dawley | 62 | 2023 | 282 | 3.100 |
Why?
|
| Placenta | 24 | 2022 | 58 | 3.070 |
Why?
|
| Heart Rate, Fetal | 18 | 2023 | 20 | 3.060 |
Why?
|
| Fetal Blood | 38 | 2018 | 41 | 2.690 |
Why?
|
| Hypothalamus | 18 | 2024 | 49 | 2.530 |
Why?
|
| Appetite | 9 | 2020 | 15 | 2.480 |
Why?
|
| Brain | 17 | 2023 | 94 | 2.200 |
Why?
|
| Arcuate Nucleus of Hypothalamus | 7 | 2020 | 10 | 2.180 |
Why?
|
| Adipose Tissue | 8 | 2022 | 69 | 2.130 |
Why?
|
| Hyperphagia | 6 | 2020 | 7 | 2.110 |
Why?
|
| Arginine Vasopressin | 33 | 2008 | 46 | 2.010 |
Why?
|
| Breast Feeding | 5 | 2025 | 14 | 1.920 |
Why?
|
| Metabolic Syndrome | 7 | 2018 | 35 | 1.820 |
Why?
|
| Overweight | 3 | 2025 | 30 | 1.770 |
Why?
|
| Pregnancy Complications | 13 | 2018 | 44 | 1.770 |
Why?
|
| Amnion | 12 | 2011 | 15 | 1.770 |
Why?
|
| Neurons | 9 | 2020 | 50 | 1.750 |
Why?
|
| Aquaporins | 8 | 2010 | 11 | 1.730 |
Why?
|
| Diet, High-Fat | 11 | 2024 | 59 | 1.720 |
Why?
|
| Infant, Newborn | 24 | 2025 | 199 | 1.720 |
Why?
|
| Fetal Hypoxia | 6 | 2015 | 10 | 1.670 |
Why?
|
| Male | 44 | 2026 | 3671 | 1.640 |
Why?
|
| Leptin | 9 | 2011 | 21 | 1.630 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 12 | 2018 | 16 | 1.620 |
Why?
|
| Birth Weight | 15 | 2017 | 33 | 1.620 |
Why?
|
| Labor, Obstetric | 11 | 2023 | 14 | 1.590 |
Why?
|
| Lactation | 5 | 2026 | 11 | 1.590 |
Why?
|
| Milk, Human | 4 | 2025 | 12 | 1.470 |
Why?
|
| Pregnancy, Animal | 12 | 2008 | 15 | 1.470 |
Why?
|
| Inflammation | 11 | 2022 | 143 | 1.460 |
Why?
|
| Diabetes, Gestational | 7 | 2014 | 14 | 1.460 |
Why?
|
| Adult | 36 | 2025 | 2113 | 1.450 |
Why?
|
| Delivery, Obstetric | 5 | 2025 | 16 | 1.430 |
Why?
|
| Fetofetal Transfusion | 6 | 2021 | 8 | 1.360 |
Why?
|
| Gestational Age | 26 | 2021 | 58 | 1.360 |
Why?
|
| Umbilical Cord | 7 | 2020 | 9 | 1.350 |
Why?
|
| Disease Models, Animal | 26 | 2023 | 231 | 1.350 |
Why?
|
| Insulin | 7 | 2018 | 146 | 1.330 |
Why?
|
| Oligohydramnios | 10 | 2010 | 12 | 1.320 |
Why?
|
| Kidney | 19 | 2008 | 184 | 1.320 |
Why?
|
| Gene Expression Regulation, Developmental | 10 | 2015 | 34 | 1.310 |
Why?
|
| Meconium | 7 | 2008 | 8 | 1.300 |
Why?
|
| Neuropeptide Y | 9 | 2016 | 13 | 1.290 |
Why?
|
| Neural Stem Cells | 3 | 2019 | 8 | 1.280 |
Why?
|
| Inflammation Mediators | 6 | 2021 | 30 | 1.270 |
Why?
|
| Cell Differentiation | 7 | 2020 | 101 | 1.250 |
Why?
|
| Angiotensin II | 10 | 2005 | 18 | 1.240 |
Why?
|
| Osmolar Concentration | 37 | 2010 | 47 | 1.240 |
Why?
|
| Fetal Diseases | 7 | 2023 | 10 | 1.230 |
Why?
|
| Lipopolysaccharides | 15 | 2022 | 41 | 1.220 |
Why?
|
| Hypertension | 9 | 2013 | 147 | 1.170 |
Why?
|
| Water-Electrolyte Balance | 10 | 2005 | 15 | 1.170 |
Why?
|
| Sodium | 16 | 2004 | 43 | 1.160 |
Why?
|
| Acetylcysteine | 6 | 2023 | 9 | 1.150 |
Why?
|
| Feeding Behavior | 8 | 2018 | 38 | 1.120 |
Why?
|
| Hypoxia, Brain | 3 | 2021 | 4 | 1.110 |
Why?
|
| Fetal Nutrition Disorders | 4 | 2009 | 9 | 1.090 |
Why?
|
| Embryonic and Fetal Development | 15 | 2004 | 16 | 1.090 |
Why?
|
| Cell Proliferation | 6 | 2019 | 143 | 1.070 |
Why?
|
| Gastrointestinal Motility | 7 | 2008 | 8 | 1.070 |
Why?
|
| Magnesium Sulfate | 7 | 2022 | 9 | 1.070 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2017 | 21 | 1.040 |
Why?
|
| Labor Stage, Second | 4 | 2025 | 5 | 1.040 |
Why?
|
| Hydrogen-Ion Concentration | 11 | 2015 | 34 | 1.030 |
Why?
|
| Prenatal Care | 6 | 2011 | 13 | 1.030 |
Why?
|
| Brain Injuries | 6 | 2023 | 12 | 1.020 |
Why?
|
| Adipogenesis | 4 | 2018 | 13 | 1.020 |
Why?
|
| Cyclic AMP | 4 | 2008 | 30 | 0.980 |
Why?
|
| Immune System | 1 | 2026 | 14 | 0.970 |
Why?
|
| Birth Injuries | 3 | 2018 | 6 | 0.960 |
Why?
|
| Blood Pressure | 20 | 2013 | 112 | 0.950 |
Why?
|
| Cervix Uteri | 4 | 2016 | 9 | 0.950 |
Why?
|
| Pregnancy Outcome | 8 | 2011 | 42 | 0.950 |
Why?
|
| RNA, Messenger | 17 | 2022 | 190 | 0.950 |
Why?
|
| Phenols | 4 | 2018 | 9 | 0.940 |
Why?
|
| Benzhydryl Compounds | 4 | 2018 | 13 | 0.930 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2025 | 3 | 0.920 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2025 | 6 | 0.920 |
Why?
|
| Sucrose | 6 | 2005 | 13 | 0.910 |
Why?
|
| Adiposity | 4 | 2022 | 20 | 0.900 |
Why?
|
| Neurogenesis | 5 | 2020 | 13 | 0.900 |
Why?
|
| Deamino Arginine Vasopressin | 10 | 2003 | 13 | 0.900 |
Why?
|
| Dystocia | 5 | 2006 | 5 | 0.890 |
Why?
|
| Satiation | 4 | 2020 | 5 | 0.890 |
Why?
|
| Mice | 11 | 2024 | 746 | 0.850 |
Why?
|
| Dehydration | 14 | 2005 | 15 | 0.840 |
Why?
|
| Pregnancy, Twin | 4 | 2021 | 4 | 0.840 |
Why?
|
| Cerebral Palsy | 3 | 2023 | 4 | 0.840 |
Why?
|
| Fetal Monitoring | 5 | 2012 | 6 | 0.840 |
Why?
|
| Body Weight | 14 | 2016 | 90 | 0.820 |
Why?
|
| Fetal Weight | 6 | 2017 | 6 | 0.800 |
Why?
|
| Lipoprotein Lipase | 2 | 2022 | 6 | 0.790 |
Why?
|
| Premature Birth | 2 | 2016 | 8 | 0.790 |
Why?
|
| Mammary Glands, Animal | 1 | 2022 | 2 | 0.770 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 15 | 2014 | 90 | 0.770 |
Why?
|
| Water Deprivation | 5 | 2007 | 5 | 0.760 |
Why?
|
| Twins, Monozygotic | 7 | 2021 | 8 | 0.760 |
Why?
|
| Apoptosis | 7 | 2022 | 179 | 0.760 |
Why?
|
| Saline Solution, Hypertonic | 7 | 2003 | 9 | 0.760 |
Why?
|
| Gene Expression | 6 | 2007 | 77 | 0.740 |
Why?
|
| Obstetric Labor Complications | 3 | 2014 | 6 | 0.730 |
Why?
|
| Parturition | 2 | 2020 | 5 | 0.720 |
Why?
|
| Liver | 11 | 2021 | 157 | 0.720 |
Why?
|
| Hypernatremia | 4 | 2005 | 9 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-fos | 5 | 2001 | 5 | 0.710 |
Why?
|
| Colon | 4 | 2008 | 20 | 0.710 |
Why?
|
| Head | 1 | 2021 | 1 | 0.700 |
Why?
|
| Labor Presentation | 1 | 2021 | 1 | 0.700 |
Why?
|
| DNA Methylation | 2 | 2019 | 26 | 0.700 |
Why?
|
| Patient Readmission | 1 | 2021 | 24 | 0.690 |
Why?
|
| Child Development | 1 | 2021 | 21 | 0.690 |
Why?
|
| Epigenesis, Genetic | 6 | 2016 | 36 | 0.690 |
Why?
|
| Neuroprotective Agents | 5 | 2021 | 14 | 0.680 |
Why?
|
| Estrogens, Non-Steroidal | 2 | 2018 | 3 | 0.680 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2020 | 4 | 0.670 |
Why?
|
| Aging | 7 | 2010 | 105 | 0.670 |
Why?
|
| Sodium Chloride | 12 | 2004 | 13 | 0.660 |
Why?
|
| PPAR gamma | 5 | 2015 | 51 | 0.660 |
Why?
|
| Cytokines | 6 | 2018 | 80 | 0.650 |
Why?
|
| Dietary Fats | 3 | 2018 | 19 | 0.650 |
Why?
|
| Postpartum Period | 4 | 2025 | 14 | 0.650 |
Why?
|
| Epithelial Cells | 4 | 2022 | 49 | 0.630 |
Why?
|
| Polyhydramnios | 6 | 2021 | 6 | 0.630 |
Why?
|
| Developmental Biology | 1 | 2019 | 1 | 0.620 |
Why?
|
| Agouti-Related Protein | 6 | 2020 | 7 | 0.620 |
Why?
|
| Anniversaries and Special Events | 1 | 2019 | 3 | 0.620 |
Why?
|
| Immunohistochemistry | 12 | 2012 | 118 | 0.620 |
Why?
|
| Publishing | 1 | 2019 | 11 | 0.620 |
Why?
|
| Body Composition | 4 | 2024 | 47 | 0.620 |
Why?
|
| Maternal-Fetal Exchange | 12 | 2012 | 20 | 0.620 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 12 | 0.620 |
Why?
|
| Appetite Regulation | 2 | 2012 | 5 | 0.610 |
Why?
|
| Quality of Life | 1 | 2021 | 184 | 0.600 |
Why?
|
| Adipocytes | 2 | 2018 | 31 | 0.590 |
Why?
|
| Jurisprudence | 1 | 2018 | 2 | 0.590 |
Why?
|
| Time Factors | 11 | 2025 | 321 | 0.590 |
Why?
|
| Endocrine Disruptors | 1 | 2018 | 3 | 0.580 |
Why?
|
| Body Mass Index | 5 | 2025 | 145 | 0.580 |
Why?
|
| Electrocardiography | 5 | 2007 | 36 | 0.570 |
Why?
|
| Extraembryonic Membranes | 5 | 2005 | 6 | 0.570 |
Why?
|
| Sirtuin 1 | 3 | 2014 | 8 | 0.570 |
Why?
|
| Cervical Length Measurement | 2 | 2016 | 2 | 0.570 |
Why?
|
| Cannabis | 1 | 2018 | 9 | 0.560 |
Why?
|
| Cardiovascular System | 10 | 2005 | 21 | 0.560 |
Why?
|
| Pro-Opiomelanocortin | 7 | 2024 | 21 | 0.560 |
Why?
|
| Food Deprivation | 6 | 2018 | 7 | 0.550 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 2 | 2008 | 7 | 0.550 |
Why?
|
| Anthropometry | 2 | 2008 | 16 | 0.550 |
Why?
|
| Esophagus | 7 | 2005 | 13 | 0.550 |
Why?
|
| Fetal Distress | 3 | 2007 | 4 | 0.550 |
Why?
|
| Diuresis | 13 | 2003 | 14 | 0.550 |
Why?
|
| Vacuum Extraction, Obstetrical | 2 | 2012 | 3 | 0.540 |
Why?
|
| Cesarean Section | 5 | 2022 | 18 | 0.530 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 5 | 2020 | 9 | 0.530 |
Why?
|
| Shoulder | 4 | 2006 | 6 | 0.530 |
Why?
|
| Water | 5 | 2007 | 13 | 0.520 |
Why?
|
| Blood Gas Analysis | 6 | 2020 | 12 | 0.520 |
Why?
|
| Weaning | 4 | 2022 | 6 | 0.520 |
Why?
|
| Obstetric Labor, Premature | 6 | 2010 | 9 | 0.510 |
Why?
|
| Ultrasonography | 2 | 2016 | 38 | 0.510 |
Why?
|
| Fatty Acids | 5 | 2024 | 25 | 0.500 |
Why?
|
| Atrial Natriuretic Factor | 14 | 1994 | 21 | 0.500 |
Why?
|
| Up-Regulation | 6 | 2016 | 94 | 0.500 |
Why?
|
| Electromyography | 13 | 2005 | 20 | 0.490 |
Why?
|
| Mitochondria | 2 | 2018 | 37 | 0.490 |
Why?
|
| Risk Factors | 12 | 2021 | 767 | 0.490 |
Why?
|
| Nitric Oxide | 3 | 2002 | 47 | 0.490 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 4 | 0.480 |
Why?
|
| Eating | 4 | 2018 | 31 | 0.470 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2007 | 21 | 0.470 |
Why?
|
| Encephalitis | 2 | 2012 | 6 | 0.460 |
Why?
|
| Chorion | 3 | 2005 | 3 | 0.460 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 120 | 0.450 |
Why?
|
| Signal Transduction | 7 | 2016 | 246 | 0.450 |
Why?
|
| Antioxidants | 5 | 2021 | 37 | 0.450 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2014 | 5 | 0.440 |
Why?
|
| Oxygen | 7 | 2020 | 44 | 0.440 |
Why?
|
| Placentation | 3 | 2014 | 12 | 0.430 |
Why?
|
| Triglycerides | 6 | 2022 | 58 | 0.430 |
Why?
|
| Caloric Restriction | 3 | 2009 | 13 | 0.430 |
Why?
|
| Bradycardia | 1 | 2014 | 5 | 0.420 |
Why?
|
| Hypoxia | 4 | 2023 | 37 | 0.420 |
Why?
|
| Plasma | 2 | 2005 | 6 | 0.420 |
Why?
|
| Atropine | 4 | 2003 | 17 | 0.420 |
Why?
|
| Blood | 5 | 2003 | 5 | 0.420 |
Why?
|
| Hemorrhage | 2 | 2005 | 23 | 0.420 |
Why?
|
| Renal Agents | 3 | 1999 | 4 | 0.410 |
Why?
|
| Maternal Exposure | 3 | 2018 | 17 | 0.410 |
Why?
|
| Nucleus Accumbens | 4 | 2018 | 9 | 0.410 |
Why?
|
| Stress, Physiological | 3 | 2008 | 19 | 0.410 |
Why?
|
| Models, Biological | 4 | 2014 | 64 | 0.410 |
Why?
|
| Cholestasis | 1 | 2013 | 7 | 0.410 |
Why?
|
| Asphyxia Neonatorum | 3 | 2021 | 3 | 0.400 |
Why?
|
| Cells, Cultured | 5 | 2018 | 234 | 0.400 |
Why?
|
| Muscle Contraction | 4 | 2007 | 13 | 0.400 |
Why?
|
| Sex Characteristics | 2 | 2015 | 39 | 0.400 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 16 | 0.390 |
Why?
|
| Overnutrition | 3 | 2020 | 4 | 0.390 |
Why?
|
| Growth and Development | 1 | 2013 | 1 | 0.390 |
Why?
|
| Adenylate Kinase | 2 | 2012 | 4 | 0.390 |
Why?
|
| Hyponatremia | 4 | 2003 | 20 | 0.390 |
Why?
|
| Receptors, Cholinergic | 2 | 2003 | 3 | 0.390 |
Why?
|
| Blood Glucose | 4 | 2015 | 188 | 0.390 |
Why?
|
| Lactic Acid | 1 | 2012 | 8 | 0.380 |
Why?
|
| Behavior, Animal | 4 | 2000 | 30 | 0.380 |
Why?
|
| Prenatal Diagnosis | 4 | 2009 | 11 | 0.380 |
Why?
|
| Oxidative Stress | 5 | 2022 | 102 | 0.380 |
Why?
|
| Ion Channels | 2 | 2003 | 14 | 0.380 |
Why?
|
| Organ Size | 7 | 2010 | 31 | 0.380 |
Why?
|
| Chronic Disease | 2 | 2015 | 167 | 0.370 |
Why?
|
| Infant | 5 | 2025 | 187 | 0.370 |
Why?
|
| Bethanechol | 3 | 2007 | 4 | 0.370 |
Why?
|
| Enterocolitis, Necrotizing | 2 | 2023 | 7 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2023 | 48 | 0.370 |
Why?
|
| Hypoxia-Ischemia, Brain | 2 | 2021 | 3 | 0.360 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2021 | 2 | 0.350 |
Why?
|
| Cardiotocography | 2 | 2023 | 4 | 0.350 |
Why?
|
| Ghrelin | 2 | 2008 | 4 | 0.350 |
Why?
|
| Aquaporin 1 | 2 | 2008 | 2 | 0.340 |
Why?
|
| Thirst | 5 | 2004 | 5 | 0.340 |
Why?
|
| Neovascularization, Physiologic | 2 | 2010 | 8 | 0.340 |
Why?
|
| Prospective Studies | 7 | 2025 | 331 | 0.340 |
Why?
|
| Blotting, Western | 6 | 2012 | 110 | 0.340 |
Why?
|
| Basal Metabolism | 1 | 2011 | 2 | 0.340 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 58 | 0.340 |
Why?
|
| Nitric Oxide Synthase Type I | 7 | 2021 | 19 | 0.340 |
Why?
|
| Glucocorticoids | 4 | 2011 | 65 | 0.340 |
Why?
|
| Tight Junctions | 1 | 2011 | 2 | 0.340 |
Why?
|
| Transcription Factor HES-1 | 3 | 2016 | 3 | 0.340 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2021 | 28 | 0.340 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 98 | 0.340 |
Why?
|
| Risk Assessment | 3 | 2016 | 197 | 0.330 |
Why?
|
| Meconium Aspiration Syndrome | 2 | 2005 | 3 | 0.330 |
Why?
|
| Uterus | 2 | 2007 | 15 | 0.330 |
Why?
|
| Pituitary Gland | 2 | 2002 | 40 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 28 | 0.330 |
Why?
|
| Injections, Intraventricular | 8 | 2004 | 21 | 0.330 |
Why?
|
| Diet | 4 | 2022 | 111 | 0.330 |
Why?
|
| Digestive System | 4 | 2005 | 6 | 0.320 |
Why?
|
| Models, Animal | 3 | 2016 | 23 | 0.320 |
Why?
|
| Ventromedial Hypothalamic Nucleus | 1 | 2010 | 2 | 0.320 |
Why?
|
| Action Potentials | 1 | 2010 | 6 | 0.320 |
Why?
|
| Serotonin | 1 | 2010 | 5 | 0.320 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2010 | 6 | 0.320 |
Why?
|
| Glyburide | 1 | 2009 | 5 | 0.320 |
Why?
|
| Lung | 6 | 2009 | 106 | 0.310 |
Why?
|
| Muscarinic Agonists | 2 | 2007 | 2 | 0.310 |
Why?
|
| Anorexia | 2 | 2007 | 8 | 0.310 |
Why?
|
| Down Syndrome | 1 | 2009 | 3 | 0.310 |
Why?
|
| Nerve Tissue Proteins | 4 | 2016 | 25 | 0.310 |
Why?
|
| Aquaporin 3 | 2 | 2006 | 3 | 0.310 |
Why?
|
| Heart Defects, Congenital | 2 | 2021 | 6 | 0.310 |
Why?
|
| Pregnancy in Diabetics | 2 | 2007 | 8 | 0.300 |
Why?
|
| Homeostasis | 7 | 2006 | 40 | 0.290 |
Why?
|
| Interleukin-6 | 7 | 2022 | 45 | 0.290 |
Why?
|
| Fatty Liver | 4 | 2013 | 59 | 0.290 |
Why?
|
| Sex Factors | 6 | 2016 | 155 | 0.280 |
Why?
|
| Fasting | 2 | 2006 | 31 | 0.280 |
Why?
|
| Trophoblasts | 1 | 2008 | 8 | 0.280 |
Why?
|
| Cell Membrane | 2 | 2006 | 54 | 0.280 |
Why?
|
| Retrospective Studies | 4 | 2022 | 681 | 0.280 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 165 | 0.270 |
Why?
|
| Infant Nutrition Disorders | 1 | 2007 | 1 | 0.270 |
Why?
|
| Blood Volume | 6 | 2005 | 8 | 0.270 |
Why?
|
| Brain Chemistry | 2 | 2004 | 7 | 0.270 |
Why?
|
| Electrolytes | 3 | 2010 | 5 | 0.270 |
Why?
|
| Appetite Depressants | 1 | 2007 | 1 | 0.260 |
Why?
|
| Organogenesis | 1 | 2007 | 7 | 0.260 |
Why?
|
| Urine | 8 | 1998 | 14 | 0.260 |
Why?
|
| Vascular Diseases | 1 | 2007 | 10 | 0.260 |
Why?
|
| Second Messenger Systems | 1 | 2007 | 6 | 0.260 |
Why?
|
| Intestine, Small | 2 | 2005 | 8 | 0.260 |
Why?
|
| Muscle, Smooth | 1 | 2007 | 22 | 0.260 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2007 | 31 | 0.260 |
Why?
|
| Ventricular Remodeling | 1 | 2007 | 5 | 0.260 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 75 | 0.260 |
Why?
|
| Fluid Therapy | 4 | 1993 | 10 | 0.260 |
Why?
|
| Ileum | 2 | 2023 | 7 | 0.260 |
Why?
|
| Diseases in Twins | 4 | 2021 | 5 | 0.250 |
Why?
|
| Nitric Oxide Synthase | 4 | 2016 | 39 | 0.250 |
Why?
|
| Body Fluids | 4 | 1998 | 8 | 0.250 |
Why?
|
| Phenotype | 4 | 2015 | 91 | 0.250 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 22 | 0.250 |
Why?
|
| Joint Dislocations | 1 | 2006 | 2 | 0.250 |
Why?
|
| Heart | 2 | 2011 | 25 | 0.250 |
Why?
|
| Alzheimer Disease | 1 | 2007 | 30 | 0.250 |
Why?
|
| Neck Injuries | 1 | 2006 | 7 | 0.250 |
Why?
|
| Carbon Dioxide | 4 | 2002 | 17 | 0.250 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2013 | 4 | 0.250 |
Why?
|
| Electroencephalography | 5 | 2014 | 17 | 0.250 |
Why?
|
| Sheep, Domestic | 5 | 2011 | 7 | 0.250 |
Why?
|
| Cerebral Ventricles | 2 | 2003 | 5 | 0.240 |
Why?
|
| Spleen | 1 | 2026 | 13 | 0.240 |
Why?
|
| Receptors, Vasopressin | 5 | 1998 | 7 | 0.240 |
Why?
|
| Reference Values | 6 | 2007 | 56 | 0.240 |
Why?
|
| Cerebral Cortex | 4 | 2011 | 15 | 0.240 |
Why?
|
| STAT3 Transcription Factor | 3 | 2011 | 16 | 0.240 |
Why?
|
| Hematocrit | 8 | 2004 | 12 | 0.240 |
Why?
|
| Lipid Metabolism | 2 | 2021 | 33 | 0.240 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 506 | 0.230 |
Why?
|
| Parasympatholytics | 2 | 2003 | 4 | 0.230 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2005 | 18 | 0.230 |
Why?
|
| Mothers | 2 | 2018 | 17 | 0.230 |
Why?
|
| Food Preferences | 2 | 2015 | 2 | 0.230 |
Why?
|
| Tyrosine 3-Monooxygenase | 4 | 2018 | 5 | 0.230 |
Why?
|
| Scalp | 2 | 2002 | 2 | 0.230 |
Why?
|
| Transcription Factor RelA | 3 | 2021 | 7 | 0.230 |
Why?
|
| Cholinergic Agents | 1 | 2005 | 2 | 0.230 |
Why?
|
| Membrane Proteins | 1 | 2005 | 48 | 0.230 |
Why?
|
| Primary Prevention | 2 | 2003 | 22 | 0.230 |
Why?
|
| Oligosaccharides | 1 | 2025 | 4 | 0.220 |
Why?
|
| Feces | 1 | 2025 | 7 | 0.220 |
Why?
|
| Starvation | 1 | 2005 | 3 | 0.220 |
Why?
|
| Disasters | 1 | 2005 | 4 | 0.220 |
Why?
|
| Drinking Behavior | 3 | 2000 | 5 | 0.220 |
Why?
|
| Progesterone | 2 | 2021 | 14 | 0.220 |
Why?
|
| Drinking | 4 | 2010 | 11 | 0.220 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 127 | 0.220 |
Why?
|
| Heart Rate | 6 | 2005 | 29 | 0.220 |
Why?
|
| Urination | 2 | 1996 | 2 | 0.220 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 11 | 0.220 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 26 | 0.220 |
Why?
|
| Adolescent | 5 | 2016 | 869 | 0.220 |
Why?
|
| Kidney Glomerulus | 4 | 2007 | 29 | 0.210 |
Why?
|
| Receptors, Leptin | 3 | 2011 | 5 | 0.210 |
Why?
|
| Plasma Volume | 1 | 2004 | 3 | 0.210 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2007 | 6 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2008 | 15 | 0.210 |
Why?
|
| Potassium | 3 | 1999 | 26 | 0.210 |
Why?
|
| Aorta | 3 | 2010 | 20 | 0.210 |
Why?
|
| Neuropeptides | 1 | 2024 | 6 | 0.210 |
Why?
|
| Cocaine | 2 | 1995 | 22 | 0.210 |
Why?
|
| Pre-Eclampsia | 2 | 2002 | 12 | 0.210 |
Why?
|
| Receptors, Muscarinic | 1 | 2003 | 1 | 0.210 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2023 | 7 | 0.200 |
Why?
|
| Receptors, Angiotensin | 2 | 2001 | 4 | 0.200 |
Why?
|
| Ganglionic Stimulants | 1 | 2003 | 3 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 10 | 0.200 |
Why?
|
| Nutritional Status | 1 | 2024 | 64 | 0.200 |
Why?
|
| Rodentia | 2 | 2023 | 4 | 0.200 |
Why?
|
| Obstetrics | 2 | 2018 | 18 | 0.200 |
Why?
|
| Bucladesine | 1 | 2003 | 4 | 0.200 |
Why?
|
| Testosterone | 1 | 2003 | 50 | 0.200 |
Why?
|
| NF-kappa B | 3 | 2021 | 56 | 0.190 |
Why?
|
| Milk Proteins | 1 | 2022 | 1 | 0.190 |
Why?
|
| Palmitates | 1 | 2022 | 5 | 0.190 |
Why?
|
| Corticosterone | 2 | 2014 | 24 | 0.190 |
Why?
|
| Liability, Legal | 2 | 2021 | 2 | 0.190 |
Why?
|
| Incidence | 3 | 2018 | 197 | 0.190 |
Why?
|
| Creatinine | 2 | 2001 | 48 | 0.190 |
Why?
|
| Smoking | 1 | 2003 | 86 | 0.190 |
Why?
|
| Muscarinic Antagonists | 2 | 2003 | 2 | 0.190 |
Why?
|
| C-Reactive Protein | 3 | 2012 | 36 | 0.190 |
Why?
|
| Tocolytic Agents | 1 | 2002 | 1 | 0.190 |
Why?
|
| Young Adult | 4 | 2025 | 567 | 0.190 |
Why?
|
| Colforsin | 3 | 2008 | 7 | 0.190 |
Why?
|
| Adaptation, Physiological | 2 | 2005 | 13 | 0.190 |
Why?
|
| Magnesium | 1 | 2002 | 5 | 0.190 |
Why?
|
| Administration, Sublingual | 4 | 2005 | 4 | 0.180 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2002 | 1 | 0.180 |
Why?
|
| Child | 3 | 2021 | 524 | 0.180 |
Why?
|
| Microcirculation | 1 | 2002 | 14 | 0.180 |
Why?
|
| Twins, Conjoined | 1 | 2021 | 1 | 0.180 |
Why?
|
| Single Umbilical Artery | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cholesterol | 3 | 2013 | 37 | 0.180 |
Why?
|
| Clavicle | 1 | 2001 | 2 | 0.180 |
Why?
|
| Saralasin | 1 | 2001 | 1 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2021 | 54 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 12 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2021 | 3 | 0.180 |
Why?
|
| Malpractice | 1 | 2021 | 2 | 0.180 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 3 | 0.180 |
Why?
|
| New York | 1 | 2021 | 7 | 0.170 |
Why?
|
| Genes, fos | 1 | 2001 | 1 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2018 | 10 | 0.170 |
Why?
|
| Family | 1 | 2021 | 27 | 0.170 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 9 | 0.170 |
Why?
|
| Hospitals, Private | 1 | 2021 | 2 | 0.170 |
Why?
|
| Receptors, Notch | 2 | 2011 | 5 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2021 | 4 | 0.170 |
Why?
|
| Neuroimmunomodulation | 1 | 2021 | 4 | 0.170 |
Why?
|
| Child, Preschool | 2 | 2021 | 258 | 0.170 |
Why?
|
| Stimulation, Chemical | 4 | 2005 | 15 | 0.170 |
Why?
|
| Nicotine | 1 | 2003 | 144 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2000 | 7 | 0.170 |
Why?
|
| Diet, Western | 1 | 2020 | 8 | 0.170 |
Why?
|
| Appetite Stimulants | 1 | 2000 | 4 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 5 | 2005 | 115 | 0.170 |
Why?
|
| Urodynamics | 1 | 2000 | 4 | 0.170 |
Why?
|
| Rumen | 2 | 1991 | 2 | 0.160 |
Why?
|
| Infusions, Intravenous | 7 | 2003 | 22 | 0.160 |
Why?
|
| Monitoring, Physiologic | 2 | 2004 | 16 | 0.160 |
Why?
|
| Probability | 3 | 2007 | 20 | 0.160 |
Why?
|
| Endocrine Glands | 2 | 2004 | 3 | 0.160 |
Why?
|
| Term Birth | 3 | 2014 | 3 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2019 | 8 | 0.160 |
Why?
|
| Pyridines | 3 | 2010 | 24 | 0.160 |
Why?
|
| Intensive Care, Neonatal | 1 | 1999 | 2 | 0.160 |
Why?
|
| Managed Care Programs | 1 | 1999 | 8 | 0.150 |
Why?
|
| Aldosterone | 1 | 1999 | 8 | 0.150 |
Why?
|
| Fetal Death | 3 | 2021 | 6 | 0.150 |
Why?
|
| Dopamine | 1 | 2018 | 12 | 0.150 |
Why?
|
| Umbilical Arteries | 1 | 2018 | 2 | 0.150 |
Why?
|
| Receptors, Cell Surface | 3 | 2007 | 29 | 0.150 |
Why?
|
| Twins | 3 | 2005 | 4 | 0.150 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 10 | 0.140 |
Why?
|
| Caspase 3 | 4 | 2022 | 27 | 0.140 |
Why?
|
| Hemodynamics | 4 | 2002 | 34 | 0.140 |
Why?
|
| Reward | 2 | 2016 | 18 | 0.140 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2018 | 1 | 0.140 |
Why?
|
| Lythraceae | 1 | 2018 | 1 | 0.140 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2015 | 3 | 0.140 |
Why?
|
| Prognosis | 1 | 2019 | 220 | 0.140 |
Why?
|
| Enzyme Inhibitors | 4 | 2003 | 53 | 0.140 |
Why?
|
| Arteries | 5 | 2003 | 15 | 0.130 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 3 | 1994 | 3 | 0.130 |
Why?
|
| Arterioles | 2 | 2007 | 8 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2008 | 14 | 0.130 |
Why?
|
| Betamethasone | 1 | 1997 | 4 | 0.130 |
Why?
|
| Thyroxine | 1 | 1997 | 33 | 0.130 |
Why?
|
| Larynx | 1 | 1997 | 3 | 0.130 |
Why?
|
| Respiratory Mechanics | 1 | 1997 | 6 | 0.130 |
Why?
|
| United States | 3 | 2021 | 1019 | 0.130 |
Why?
|
| Allantois | 2 | 2005 | 2 | 0.130 |
Why?
|
| Protein Biosynthesis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 5 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 5 | 0.130 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 4 | 0.130 |
Why?
|
| Cell Culture Techniques | 2 | 2007 | 18 | 0.130 |
Why?
|
| Nerve Growth Factors | 2 | 2011 | 4 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 5 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 23 | 0.120 |
Why?
|
| Litter Size | 2 | 2007 | 2 | 0.120 |
Why?
|
| Kidney Diseases | 2 | 2011 | 121 | 0.120 |
Why?
|
| Peptide Hormones | 2 | 2006 | 5 | 0.120 |
Why?
|
| Taste Perception | 1 | 2016 | 1 | 0.120 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 6 | 0.120 |
Why?
|
| alpha-MSH | 1 | 2016 | 3 | 0.120 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 3 | 0.120 |
Why?
|
| Synaptic Potentials | 1 | 2016 | 2 | 0.120 |
Why?
|
| Gastrointestinal Contents | 1 | 1996 | 2 | 0.120 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2016 | 3 | 0.120 |
Why?
|
| Intestinal Absorption | 1 | 1996 | 7 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 14 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 155 | 0.120 |
Why?
|
| Receptors, Opioid, mu | 1 | 2016 | 19 | 0.120 |
Why?
|
| Energy Intake | 1 | 2016 | 30 | 0.120 |
Why?
|
| Cell Line | 2 | 2008 | 124 | 0.120 |
Why?
|
| Extraction, Obstetrical | 1 | 1995 | 1 | 0.120 |
Why?
|
| Avoidance Learning | 1 | 2015 | 2 | 0.120 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 3 | 0.120 |
Why?
|
| Body Size | 1 | 2015 | 8 | 0.120 |
Why?
|
| Rabbits | 4 | 2005 | 48 | 0.120 |
Why?
|
| Differential Threshold | 3 | 2003 | 3 | 0.120 |
Why?
|
| Pancreas | 2 | 2007 | 144 | 0.120 |
Why?
|
| Hypertonic Solutions | 3 | 2003 | 3 | 0.120 |
Why?
|
| Algorithms | 2 | 2008 | 83 | 0.110 |
Why?
|
| Prefrontal Cortex | 1 | 2015 | 1 | 0.110 |
Why?
|
| Attention | 1 | 2015 | 3 | 0.110 |
Why?
|
| Food | 1 | 2015 | 8 | 0.110 |
Why?
|
| Epigenomics | 1 | 2015 | 2 | 0.110 |
Why?
|
| Syndrome | 2 | 2005 | 32 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 12 | 0.110 |
Why?
|
| Fluorescein | 3 | 2005 | 6 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 43 | 0.110 |
Why?
|
| Menopause, Premature | 1 | 2014 | 2 | 0.110 |
Why?
|
| Program Evaluation | 2 | 2011 | 46 | 0.110 |
Why?
|
| Weight Gain | 2 | 2024 | 28 | 0.110 |
Why?
|
| Ovary | 1 | 2014 | 19 | 0.110 |
Why?
|
| Uterine Contraction | 1 | 1994 | 3 | 0.110 |
Why?
|
| Down-Regulation | 4 | 2023 | 57 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2014 | 18 | 0.110 |
Why?
|
| Artifacts | 1 | 1994 | 5 | 0.110 |
Why?
|
| Transducers, Pressure | 1 | 1994 | 4 | 0.110 |
Why?
|
| Fetal Heart | 1 | 2014 | 3 | 0.110 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 2 | 0.110 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2014 | 5 | 0.110 |
Why?
|
| Stem Cells | 1 | 2014 | 19 | 0.110 |
Why?
|
| Injections | 3 | 2002 | 20 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2021 | 12 | 0.110 |
Why?
|
| Chlorides | 3 | 2003 | 12 | 0.110 |
Why?
|
| Cell Movement | 2 | 2011 | 38 | 0.110 |
Why?
|
| Stearic Acids | 1 | 2014 | 2 | 0.110 |
Why?
|
| Oleic Acid | 1 | 2014 | 4 | 0.110 |
Why?
|
| Lipids | 1 | 2014 | 35 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 44 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 17 | 0.100 |
Why?
|
| Respiration, Artificial | 1 | 1993 | 19 | 0.100 |
Why?
|
| Cholic Acid | 1 | 2013 | 1 | 0.100 |
Why?
|
| Lipogenesis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Bile Acids and Salts | 1 | 2013 | 12 | 0.100 |
Why?
|
| Solutions | 2 | 2004 | 3 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2013 | 9 | 0.100 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 13 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2013 | 28 | 0.100 |
Why?
|
| Renin-Angiotensin System | 1 | 2013 | 7 | 0.100 |
Why?
|
| Metabolic Diseases | 1 | 2013 | 13 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2013 | 35 | 0.100 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2013 | 7 | 0.100 |
Why?
|
| Catecholamines | 1 | 1992 | 7 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2009 | 112 | 0.100 |
Why?
|
| Norepinephrine | 4 | 2003 | 10 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 208 | 0.100 |
Why?
|
| Contrast Media | 2 | 2003 | 18 | 0.100 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 11 | 0.100 |
Why?
|
| Cytoprotection | 1 | 2012 | 5 | 0.090 |
Why?
|
| Calcium | 2 | 2010 | 117 | 0.090 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 3 | 0.090 |
Why?
|
| Learning Curve | 1 | 2012 | 3 | 0.090 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 8 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2012 | 8 | 0.090 |
Why?
|
| Perception | 1 | 2012 | 19 | 0.090 |
Why?
|
| Blotting, Northern | 2 | 2004 | 25 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2012 | 17 | 0.090 |
Why?
|
| Fetal Organ Maturity | 2 | 2009 | 6 | 0.090 |
Why?
|
| Prosencephalon | 1 | 2011 | 2 | 0.090 |
Why?
|
| Solitary Nucleus | 2 | 2003 | 2 | 0.090 |
Why?
|
| Cytochromes c | 1 | 2011 | 7 | 0.090 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2011 | 5 | 0.090 |
Why?
|
| Cytosol | 1 | 2011 | 26 | 0.090 |
Why?
|
| Caspases | 1 | 2011 | 29 | 0.090 |
Why?
|
| Fetal Movement | 1 | 2011 | 1 | 0.090 |
Why?
|
| Animal Feed | 1 | 2011 | 11 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 24 | 0.090 |
Why?
|
| Physicians | 1 | 2012 | 49 | 0.090 |
Why?
|
| Hypothalamus, Anterior | 2 | 2001 | 2 | 0.090 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2001 | 8 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 11 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2011 | 10 | 0.090 |
Why?
|
| Maternal Welfare | 1 | 2011 | 2 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2011 | 16 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2012 | 62 | 0.090 |
Why?
|
| Lactates | 1 | 2011 | 2 | 0.090 |
Why?
|
| Nephrons | 1 | 2011 | 1 | 0.090 |
Why?
|
| Age Factors | 4 | 2011 | 193 | 0.090 |
Why?
|
| Program Development | 1 | 2011 | 34 | 0.090 |
Why?
|
| Permeability | 1 | 2011 | 6 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 4 | 0.080 |
Why?
|
| Arginine | 2 | 2002 | 20 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 14 | 0.080 |
Why?
|
| Histones | 1 | 2010 | 13 | 0.080 |
Why?
|
| Electrophysiology | 2 | 2005 | 8 | 0.080 |
Why?
|
| Fenfluramine | 1 | 2010 | 1 | 0.080 |
Why?
|
| Ritanserin | 1 | 2010 | 1 | 0.080 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2010 | 1 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 2 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2013 | 2 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 72 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 21 | 0.080 |
Why?
|
| Labor Stage, Third | 2 | 2003 | 2 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 27 | 0.080 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2000 | 8 | 0.080 |
Why?
|
| Hypotension | 1 | 1990 | 8 | 0.080 |
Why?
|
| fas Receptor | 1 | 2009 | 3 | 0.080 |
Why?
|
| Membrane Lipids | 1 | 2009 | 4 | 0.080 |
Why?
|
| Imidazoles | 2 | 2004 | 13 | 0.080 |
Why?
|
| Darkness | 1 | 2009 | 1 | 0.080 |
Why?
|
| Photoperiod | 1 | 2009 | 1 | 0.080 |
Why?
|
| Catheterization | 2 | 2002 | 7 | 0.080 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2009 | 1 | 0.070 |
Why?
|
| Pulmonary Alveoli | 1 | 2009 | 33 | 0.070 |
Why?
|
| Physical Examination | 1 | 2009 | 7 | 0.070 |
Why?
|
| Myenteric Plexus | 1 | 2008 | 2 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 11 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 24 | 0.070 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2008 | 25 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2015 | 63 | 0.070 |
Why?
|
| Prevalence | 1 | 2009 | 259 | 0.070 |
Why?
|
| California | 1 | 2009 | 230 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 35 | 0.070 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 4 | 0.070 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 5 | 0.070 |
Why?
|
| Mass Screening | 1 | 2009 | 116 | 0.070 |
Why?
|
| Thionucleotides | 1 | 2008 | 1 | 0.070 |
Why?
|
| Observer Variation | 1 | 2007 | 11 | 0.070 |
Why?
|
| Splanchnic Circulation | 1 | 2007 | 3 | 0.070 |
Why?
|
| Fatty Acid Synthases | 3 | 2016 | 6 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2007 | 7 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2007 | 5 | 0.070 |
Why?
|
| Mesenteric Arteries | 1 | 2007 | 6 | 0.070 |
Why?
|
| Epinephrine | 3 | 1993 | 9 | 0.070 |
Why?
|
| Apgar Score | 2 | 1998 | 4 | 0.070 |
Why?
|
| Pirenzepine | 1 | 2007 | 1 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2007 | 13 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chemokine CCL2 | 2 | 2018 | 12 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2007 | 27 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2007 | 51 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 30 | 0.060 |
Why?
|
| Random Allocation | 2 | 2018 | 27 | 0.060 |
Why?
|
| Defecation | 1 | 2007 | 3 | 0.060 |
Why?
|
| Partial Pressure | 2 | 2002 | 2 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2007 | 30 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 30 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2007 | 18 | 0.060 |
Why?
|
| Logistic Models | 2 | 2014 | 165 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2004 | 66 | 0.060 |
Why?
|
| Obstetrical Forceps | 1 | 2006 | 2 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 13 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2006 | 20 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2007 | 74 | 0.060 |
Why?
|
| Aquaporin 2 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Natriuresis | 4 | 1994 | 5 | 0.060 |
Why?
|
| DNA Primers | 1 | 2006 | 23 | 0.060 |
Why?
|
| Absorption | 2 | 1999 | 5 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2006 | 10 | 0.060 |
Why?
|
| Dizocilpine Maleate | 1 | 2005 | 4 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 8 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2005 | 10 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 38 | 0.060 |
Why?
|
| alpha-Fetoproteins | 1 | 2005 | 6 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 43 | 0.060 |
Why?
|
| Cues | 2 | 2015 | 3 | 0.060 |
Why?
|
| Stomach | 1 | 2005 | 8 | 0.060 |
Why?
|
| Mechanics | 1 | 2005 | 1 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 9 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2003 | 11 | 0.060 |
Why?
|
| Chorioamnionitis | 2 | 2015 | 5 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 30 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2025 | 7 | 0.060 |
Why?
|
| Bacteria | 1 | 2025 | 9 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 13 | 0.060 |
Why?
|
| Losartan | 1 | 2004 | 3 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 5 | 0.060 |
Why?
|
| Infusions, Parenteral | 2 | 1994 | 7 | 0.060 |
Why?
|
| Hypotonic Solutions | 1 | 2004 | 1 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 89 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 279 | 0.050 |
Why?
|
| Growth | 1 | 2004 | 2 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 2002 | 2 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2004 | 4 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 6 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 12 | 0.050 |
Why?
|
| Osmotic Pressure | 1 | 2003 | 1 | 0.050 |
Why?
|
| Version, Fetal | 1 | 2003 | 1 | 0.050 |
Why?
|
| Parity | 1 | 2003 | 7 | 0.050 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2015 | 4 | 0.050 |
Why?
|
| Maternal Age | 1 | 2003 | 5 | 0.050 |
Why?
|
| Intestines | 1 | 2023 | 7 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 50 | 0.050 |
Why?
|
| Glutathione | 1 | 2023 | 14 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 140 | 0.050 |
Why?
|
| Acute Disease | 1 | 2003 | 91 | 0.050 |
Why?
|
| Neck Muscles | 3 | 1992 | 3 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 172 | 0.050 |
Why?
|
| Neuroprotection | 1 | 2022 | 2 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 268 | 0.050 |
Why?
|
| Half-Life | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ions | 1 | 2002 | 3 | 0.050 |
Why?
|
| Microspheres | 1 | 2002 | 2 | 0.050 |
Why?
|
| Fractals | 1 | 2002 | 1 | 0.050 |
Why?
|
| Nonlinear Dynamics | 1 | 2002 | 2 | 0.050 |
Why?
|
| Edema | 1 | 2021 | 6 | 0.050 |
Why?
|
| Subfornical Organ | 1 | 2001 | 1 | 0.050 |
Why?
|
| Preoptic Area | 1 | 2001 | 3 | 0.050 |
Why?
|
| Morbidity | 1 | 2001 | 21 | 0.050 |
Why?
|
| Proteomics | 1 | 2021 | 9 | 0.040 |
Why?
|
| Technetium | 1 | 2001 | 1 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 11 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2001 | 14 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 2001 | 21 | 0.040 |
Why?
|
| Rhombencephalon | 1 | 2001 | 1 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2001 | 2 | 0.040 |
Why?
|
| Fibronectins | 2 | 2010 | 18 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2001 | 50 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 45 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2021 | 6 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 16 | 0.040 |
Why?
|
| Vasopressins | 2 | 1992 | 9 | 0.040 |
Why?
|
| Hematoma | 1 | 2000 | 2 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2000 | 7 | 0.040 |
Why?
|
| Skull Fractures | 1 | 2000 | 3 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2000 | 5 | 0.040 |
Why?
|
| Body Water | 1 | 2000 | 4 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2000 | 11 | 0.040 |
Why?
|
| Research Design | 1 | 2001 | 41 | 0.040 |
Why?
|
| Pregnancy Trimester, First | 1 | 2021 | 18 | 0.040 |
Why?
|
| Carbohydrates | 1 | 2000 | 5 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2000 | 10 | 0.040 |
Why?
|
| Medical Records | 1 | 2000 | 23 | 0.040 |
Why?
|
| Patient Admission | 1 | 2000 | 10 | 0.040 |
Why?
|
| Kinetics | 3 | 1996 | 69 | 0.040 |
Why?
|
| Triplets | 1 | 1999 | 2 | 0.040 |
Why?
|
| Pregnancy, Multiple | 1 | 1999 | 2 | 0.040 |
Why?
|
| Wnt Proteins | 2 | 2011 | 15 | 0.040 |
Why?
|
| ROC Curve | 1 | 1999 | 28 | 0.040 |
Why?
|
| Infant, Premature | 1 | 1999 | 23 | 0.040 |
Why?
|
| Species Specificity | 1 | 1999 | 17 | 0.040 |
Why?
|
| Length of Stay | 1 | 1999 | 53 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 14 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 1999 | 27 | 0.040 |
Why?
|
| Ventral Tegmental Area | 1 | 2018 | 3 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2018 | 2 | 0.040 |
Why?
|
| Electron Transport | 1 | 2018 | 2 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 3 | 0.040 |
Why?
|
| Radioimmunoassay | 3 | 1994 | 26 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2018 | 8 | 0.030 |
Why?
|
| Transducers | 1 | 1997 | 1 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1997 | 7 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 1997 | 44 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 44 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 258 | 0.030 |
Why?
|
| Electrodiagnosis | 1 | 1997 | 1 | 0.030 |
Why?
|
| Reflex | 1 | 1997 | 1 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 64 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2016 | 2 | 0.030 |
Why?
|
| Placental Circulation | 1 | 2016 | 1 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2016 | 4 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 19 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 26 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1996 | 19 | 0.030 |
Why?
|
| Drinking Water | 1 | 2016 | 5 | 0.030 |
Why?
|
| Los Angeles | 2 | 1994 | 321 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 73 | 0.030 |
Why?
|
| Escape Reaction | 1 | 2015 | 1 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 14 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 5 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 21 | 0.030 |
Why?
|
| Maternal Behavior | 1 | 2015 | 3 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 2015 | 17 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 51 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 26 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 65 | 0.030 |
Why?
|
| Hydrostatic Pressure | 1 | 1994 | 1 | 0.030 |
Why?
|
| Endometritis | 1 | 1994 | 6 | 0.030 |
Why?
|
| Acceleration | 1 | 2014 | 1 | 0.030 |
Why?
|
| Deceleration | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 42 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 2014 | 4 | 0.030 |
Why?
|
| Exercise | 1 | 2015 | 55 | 0.030 |
Why?
|
| Fetal Macrosomia | 1 | 2014 | 2 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 14 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2014 | 3 | 0.030 |
Why?
|
| Drainage | 1 | 1994 | 10 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 4 | 0.030 |
Why?
|
| Binding Sites | 1 | 1994 | 24 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1994 | 48 | 0.030 |
Why?
|
| Constriction | 1 | 1993 | 1 | 0.030 |
Why?
|
| Ligation | 1 | 1993 | 14 | 0.030 |
Why?
|
| Renin | 2 | 1991 | 5 | 0.030 |
Why?
|
| Urea | 1 | 1992 | 15 | 0.020 |
Why?
|
| Electron Microscope Tomography | 1 | 2011 | 1 | 0.020 |
Why?
|
| Diastole | 1 | 1991 | 4 | 0.020 |
Why?
|
| Systole | 1 | 1991 | 7 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 15 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 2 | 2003 | 2 | 0.020 |
Why?
|
| Amino Acid Transport System A | 1 | 2011 | 1 | 0.020 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Gases | 1 | 2011 | 3 | 0.020 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2011 | 25 | 0.020 |
Why?
|
| Acetyl Coenzyme A | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 1991 | 22 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 17 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 10 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Thromboxane-A Synthase | 1 | 1990 | 1 | 0.020 |
Why?
|
| Prostaglandins | 1 | 1990 | 7 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1990 | 5 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2011 | 53 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1990 | 31 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 82 | 0.020 |
Why?
|
| Nitroprusside | 1 | 1990 | 3 | 0.020 |
Why?
|
| Mast Cells | 1 | 2009 | 2 | 0.020 |
Why?
|
| Microglia | 1 | 2009 | 5 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 9 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 9 | 0.020 |
Why?
|
| Hippocampus | 1 | 2009 | 19 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 10 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 1 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2009 | 3 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2009 | 9 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 39 | 0.020 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2009 | 22 | 0.020 |
Why?
|
| Craniocerebral Trauma | 1 | 1989 | 10 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2009 | 1 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 13 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 10 | 0.020 |
Why?
|
| Ureter | 1 | 2008 | 1 | 0.020 |
Why?
|
| PAX2 Transcription Factor | 1 | 2008 | 1 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Wnt4 Protein | 1 | 2008 | 2 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2008 | 3 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 7 | 0.020 |
Why?
|
| PPAR alpha | 1 | 2008 | 9 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 55 | 0.020 |
Why?
|
| Vasotocin | 1 | 1988 | 1 | 0.020 |
Why?
|
| Neurophysins | 1 | 1988 | 2 | 0.020 |
Why?
|
| Oxytocin | 1 | 1988 | 6 | 0.020 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2005 | 6 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Brain Stem | 1 | 1999 | 3 | 0.010 |
Why?
|
| Trachea | 2 | 1989 | 8 | 0.010 |
Why?
|
| Bed Rest | 1 | 1994 | 1 | 0.010 |
Why?
|
| Office Visits | 1 | 1994 | 1 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1994 | 1 | 0.010 |
Why?
|
| Counseling | 1 | 1994 | 29 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1994 | 101 | 0.010 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 1993 | 3 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1992 | 2 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1992 | 8 | 0.010 |
Why?
|
| Protein Binding | 1 | 1992 | 29 | 0.010 |
Why?
|
| Polymers | 1 | 1992 | 7 | 0.010 |
Why?
|
| Collagen | 1 | 1992 | 31 | 0.010 |
Why?
|
| Respiration | 1 | 1991 | 13 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1991 | 11 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1991 | 23 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 17 | 0.010 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1989 | 2 | 0.000 |
Why?
|
| Heart Atria | 1 | 1988 | 2 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 18 | 0.000 |
Why?
|